Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy

R. Veselska, M. Jezova, M. Kyr, P. Mazanek, P. Chlapek, V. Dobrotkova, J. Sterba,

. 2019 ; 9 (-) : 1221. [pub] 20191115

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19043949

The survival rate for patients with high-risk neuroblastomas remains poor despite new improvements in available therapeutic modalities. A detailed understanding of the mechanisms underlying clinical responses to multimodal treatment is one of the important aspects that may provide precision in the prediction of a patient's clinical outcome. Our study was designed as a detailed comparative analysis of five selected proteins (DDX39A, HMGA1, HOXC9, NF1, and PBX1) in one cohort of patients using the same methodical approaches. These proteins were already reported separately as related to the resistance or sensitivity to retinoids and as useful prognostic markers of survival probability. In the cohort of 19 patients suffering from high-risk neuroblastomas, we analyzed initial immunohistochemistry samples obtained by diagnostic biopsy and post-induction samples taken after the end of induction therapy. The expression of DDX39A, HMGA1, HOXC9, and NF1 showed varied patterns with almost no differences between responders and non-responders. Nevertheless, we found very interesting results for PBX1: non-responders had significantly higher expression levels of this protein in the initial tumor samples when compared with responders; this expression pattern changed inversely in the post-induction samples, and this change was also statistically significant. Moreover, our results from survival analyses reveal the prognostic value of PBX1, NF1, and HOXC9 expression in neuroblastoma tissue. In addition to the prognostic importance of PBX1, NF1, and HOXC9 proteins, our results demonstrated that PBX1 could be used for the prediction of the clinical response to induction chemotherapy in patients suffering from high-risk neuroblastoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19043949
003      
CZ-PrNML
005      
20200109095127.0
007      
ta
008      
200107s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2019.01221 $2 doi
035    __
$a (PubMed)31803613
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Veselska, Renata $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia. Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
245    10
$a Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy / $c R. Veselska, M. Jezova, M. Kyr, P. Mazanek, P. Chlapek, V. Dobrotkova, J. Sterba,
520    9_
$a The survival rate for patients with high-risk neuroblastomas remains poor despite new improvements in available therapeutic modalities. A detailed understanding of the mechanisms underlying clinical responses to multimodal treatment is one of the important aspects that may provide precision in the prediction of a patient's clinical outcome. Our study was designed as a detailed comparative analysis of five selected proteins (DDX39A, HMGA1, HOXC9, NF1, and PBX1) in one cohort of patients using the same methodical approaches. These proteins were already reported separately as related to the resistance or sensitivity to retinoids and as useful prognostic markers of survival probability. In the cohort of 19 patients suffering from high-risk neuroblastomas, we analyzed initial immunohistochemistry samples obtained by diagnostic biopsy and post-induction samples taken after the end of induction therapy. The expression of DDX39A, HMGA1, HOXC9, and NF1 showed varied patterns with almost no differences between responders and non-responders. Nevertheless, we found very interesting results for PBX1: non-responders had significantly higher expression levels of this protein in the initial tumor samples when compared with responders; this expression pattern changed inversely in the post-induction samples, and this change was also statistically significant. Moreover, our results from survival analyses reveal the prognostic value of PBX1, NF1, and HOXC9 expression in neuroblastoma tissue. In addition to the prognostic importance of PBX1, NF1, and HOXC9 proteins, our results demonstrated that PBX1 could be used for the prediction of the clinical response to induction chemotherapy in patients suffering from high-risk neuroblastoma.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jezova, Marta $u Department of Pathology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia.
700    1_
$a Kyr, Michal $u Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Mazanek, Pavel $u Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia.
700    1_
$a Chlapek, Petr $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Dobrotkova, Viera $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Sterba, Jaroslav $u Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 9, č. - (2019), s. 1221
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31803613 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109095456 $b ABA008
999    __
$a ind $b bmc $g 1480538 $s 1082619
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c - $d 1221 $e 20191115 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20200107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace